Keytruda and Bleeding disorders - a phase IV clinical study of FDA data

Summary:

Bleeding disorders is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Xarelto, and have Lung carcinoma cell type unspecified stage iv.

The phase IV clinical study analyzes which people have Bleeding disorders when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Bleeding disorders?

Bleeding disorders is found to be associated with 1,190 drugs and 1,649 conditions by eHealthMe. Check the latest studies of Bleeding disorders.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 21 people (0.04%) have Bleeding disorders.

Could Keytruda cause Bleeding disorders?

Among these 21 people:

How long have people been on Keytruda when they have Bleeding disorders? *

What is the gender of people who have Bleeding disorders when taking Keytruda? *

female: 35 %
male: 65 %

What is the age of people who have Bleeding disorders when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Bleeding disorders? *

Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 23.81%
Malignant Neoplasm Progression (cancer tumour came back): 5 people, 23.81%
Fatigue (feeling of tiredness): 5 people, 23.81%
Dizziness: 4 people, 19.05%
Oedema Peripheral (superficial swelling): 4 people, 19.05%
Diarrhea: 4 people, 19.05%
Cough: 4 people, 19.05%
Fall: 4 people, 19.05%
Weakness: 4 people, 19.05%
Thrombocytopenia (decrease of platelets in blood): 4 people, 19.05%

What are the existing conditions these people have? *

Pain: 4 people, 19.05%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 4 people, 19.05%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 3 people, 14.29%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 3 people, 14.29%
Nausea (feeling of having an urge to vomit): 3 people, 14.29%
Stress And Anxiety: 2 people, 9.52%
Constipation: 2 people, 9.52%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 9.52%
Herpes Simplex (herpes simplex is a common viral infection): 2 people, 9.52%
Hypophysitis (inflammation of the pituitary gland): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Bleeding disorders?

- Check whether Bleeding disorders is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bleeding disorders:

Bleeding disorders (1,190 drugs)

Browse all the conditions that are associated with Bleeding disorders:

Bleeding disorders (1,649 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.